top of page

MENU

PURMX Therapeutics Receives Orphan Drug Designation for miR-3140-3p from the U.S. FDA

  • Writer: tomokokikuchi4
    tomokokikuchi4
  • May 9
  • 1 min read

 PURMX Therapeutics Inc. (hereinafter “PURMX”), headquartered in Hiroshima, Japan and led by President and CEO Hidetoshi Tahara, announced that on May 6, 2025, it received Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) for miR-3140-3p, a naturally occurring microRNA currently under clinical development by the company. 



 
 
 

Recent Posts

See All

Comments


bottom of page